Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. Nov 6, 2016; 7(4): 550-555
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.550
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.550
Table 4 Success rate and underlying disease: Primary eradication therapy
| PPI group | Vonoprazan group | P value | ||
| ITT analysis | 72.5% (988/1362) | 86.7% (221/255) | < 0.0001 | |
| Chronic gastritis | ||||
| PP analysis | 75.1% (988/1316) | 90.6% (221/244) | < 0.0001 | |
| ITT analysis | 75.4% (187/248) | 83.6% (46/55) | 0.22 | |
| Peptic ulcer | ||||
| PP analysis | 82.7% (187/226) | 93.9% (46/49) | 0.051 | |
| ITT analysis | 76.6% (82/107) | 80% (20/25) | 0.8 | |
| After endoscopic therapy for early gastric cancer | ||||
| PP analysis | 78.1% (82/105) | 80% (20/25) | 1 |
- Citation: Yamada S, Kawakami T, Nakatsugawa Y, Suzuki T, Fujii H, Tomatsuri N, Nakamura H, Sato H, Okuyama Y, Kimura H, Yoshida N. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 2016; 7(4): 550-555
- URL: https://www.wjgnet.com/2150-5349/full/v7/i4/550.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i4.550